Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 2979-2983

  D'Amico, Anthony V ^a   Chen, Ming Hui ^a   Renshaw, Andrew A ^a   Loffredo, Brittany ^a   Kantoff, Philip W ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANDROGEN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GLEASON SCORE; HORMONE INHIBITION; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REGRESSION ANALYSIS; SIDE EFFECT; TREATMENT DURATION; ADENOCARCINOMA; BLOOD; DRUG POTENTIATION; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 46449111825     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9699     Document Type: Article

References (18)

1. Denham J, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
2. Pilepich MV, Winter K, John MJ, et al: Phase III Radiation therapy Oncology Group (RTOG) 8610 of Androgen Deprivation Adjuvant to Definitive Radiotherapy in Locally Advanced Carcinoma of the Prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
3. D'Amico AV, Manola J, Loffredo M, et al: Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
4. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-106, 2002
5. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 8531. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
7. Beahrs OH, Henson DE, Hutter RVP, et al: American Joint Committee on Cancer Staging Manual (ed 4). Philadelphia, PA, Lippincott, 1992, pp 181-186
8. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004
9. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
10. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
11. Klein JP, Moeschberger ML: Refinements of the semiparametric proportional hazards model, in Klein JP, Moeschberger ML (eds): Survival Analysis: Techniques for Censored and Truncated Data (ed 2). New York, NY, Springer, 2003, pp 295-328
12. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
13. Neter J, Wassermann W, Kutner M (eds): Simultaneous inferences and other topics in regression analyses-1, in Applied Linear Regression Models. Homewood, IL, Irwin Professional Publishing, 1983, pp 150-153
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-500, 1958
15. Agresti A: In, Agresti A (ed): An Introduction to Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2002, pp 16-52
16. D'Amico AV, Moul J, Carroll P, et al: Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
17. Valicenti RK, Desilvio M, Hanks GE, et al: Post-treatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 9202. Int J Radiat Oncol Biol Phys 66:1064-1071, 2006
18. D'Amico AV, Loffredo M, Renshaw AA, et al: Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24:4190-4195, 2006